Repligen (NASDAQ:RGEN) Shares Gap Down – What’s Next?

Shares of Repligen Corporation (NASDAQ:RGEN) gapped down prior to trading on Tuesday . The stock had previously closed at $135.40, but opened at $122.28. Repligen shares last traded at $135.75, with a volume of 518,745 shares trading hands.

Wall Street Analysts Forecast Growth

RGEN has been the subject of several research reports. Wells Fargo & Company upped their price target on shares of Repligen from $175.00 to $190.00 and gave the company an “overweight” rating in a research report on Monday, December 15th. Jefferies Financial Group set a $160.00 target price on shares of Repligen and gave the stock a “hold” rating in a research note on Tuesday, October 28th. Weiss Ratings upgraded Repligen from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, February 17th. Canaccord Genuity Group increased their price objective on Repligen from $150.00 to $165.00 and gave the stock a “hold” rating in a research report on Wednesday, October 29th. Finally, UBS Group lifted their target price on Repligen from $190.00 to $200.00 and gave the company a “buy” rating in a research note on Friday, January 16th. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, Repligen has a consensus rating of “Moderate Buy” and an average price target of $177.92.

Repligen Price Performance

The company has a current ratio of 8.36, a quick ratio of 7.14 and a debt-to-equity ratio of 0.26. The stock has a fifty day simple moving average of $156.30 and a two-hundred day simple moving average of $146.71. The company has a market cap of $7.66 billion, a PE ratio of 6,813.66, a price-to-earnings-growth ratio of 2.48 and a beta of 1.13.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings results on Tuesday, February 24th. The biotechnology company reported $0.49 EPS for the quarter, beating the consensus estimate of $0.44 by $0.05. Repligen had a return on equity of 4.66% and a net margin of 0.25%.The business had revenue of $197.91 million during the quarter, compared to analysts’ expectations of $192.23 million. During the same period last year, the firm earned $0.44 EPS. The company’s quarterly revenue was up 18.1% compared to the same quarter last year. Repligen has set its FY 2026 guidance at 1.930-2.010 EPS. On average, equities analysts predict that Repligen Corporation will post 1.72 EPS for the current fiscal year.

Insider Buying and Selling at Repligen

In other news, Director Karen A. Dawes sold 275 shares of the stock in a transaction dated Wednesday, December 17th. The shares were sold at an average price of $161.00, for a total value of $44,275.00. Following the completion of the transaction, the director owned 91,821 shares in the company, valued at $14,783,181. This trade represents a 0.30% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 1.20% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. T. Rowe Price Investment Management Inc. lifted its position in shares of Repligen by 12.9% during the 4th quarter. T. Rowe Price Investment Management Inc. now owns 646,122 shares of the biotechnology company’s stock valued at $105,874,000 after acquiring an additional 74,044 shares during the period. Compound Planning Inc. purchased a new stake in Repligen during the fourth quarter worth $204,000. Invesco Ltd. grew its holdings in Repligen by 43.9% in the fourth quarter. Invesco Ltd. now owns 1,256,439 shares of the biotechnology company’s stock valued at $205,880,000 after purchasing an additional 383,399 shares during the last quarter. Alpine Woods Capital Investors LLC purchased a new stake in shares of Repligen in the 4th quarter worth about $1,005,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Repligen in the 4th quarter worth about $204,000. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.